{"id":2968,"date":"2019-06-17T01:43:00","date_gmt":"2019-06-17T06:43:00","guid":{"rendered":"https:\/\/worldcarenew.wpenginepowered.com\/?p=2968"},"modified":"2026-03-08T02:23:25","modified_gmt":"2026-03-08T07:23:25","slug":"un-nou-instrument-dezvoltat-pentru-diagnosticarea-cazurilor-de-dementa","status":"publish","type":"post","link":"https:\/\/www.worldcare.com\/ro\/new-tool-developed-to-diagnose-dementia-cases\/","title":{"rendered":"Un nou instrument dezvoltat pentru diagnosticarea cazurilor de demen\u021b\u0103"},"content":{"rendered":"<p>De la ob\u021binerea cu succes a primei remisiuni a unui caz de cancer pediatric \u00een 1948, p\u00e2n\u0103 la crearea celor mai revolu\u021bionare realiz\u0103ri medicale\u00a0<a href=\"https:\/\/www.worldcare.com\/ro\/experienta-membrilor\/\">Consor\u021biul WorldCare<sup>\u00ae<\/sup><\/a>\u00a0Furnizorii de servicii de a doua opinie medical\u0103 (MSO), Dana-Farber \u0219i Spitalul General din Massachusetts, au creat cu succes un instrument molecular care ajut\u0103 la studierea acumul\u0103rii de proteine toxice \u00een celulele creierului pacien\u021bilor care sufer\u0103 de multiple afec\u021biuni de demen\u021b\u0103. Acest instrument molecular este denumit QC-01-175. \u00cen jurnal\u00a0<a href=\"https:\/\/elifesciences.org\/\" target=\"_blank\" rel=\"noopener\">eLife<\/a>, acest instrument a fost descris ca o modalitate de diagnosticare a bolii Alzheimer \u0219i a tulbur\u0103rilor neurodegenerative asociate.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Ce \u00eenseamn\u0103 acest lucru?<\/h3>\n\n\n\n<p>\u00cen primul r\u00e2nd, ce anume c\u0103utau ace\u0219ti cercet\u0103tori? Ei bine, pentru \u00eenceput, erau interesa\u021bi s\u0103 \u00een\u021beleag\u0103 mai bine rolul pe care \u00eel joac\u0103 proteinele aberante \u00een cazurile de demen\u021b\u0103. S\u0103 examineze \u0219i s\u0103 \u00een\u021beleag\u0103 faptul c\u0103 proteina tau joac\u0103 un rol semnificativ \u00een legarea \u0219i modelarea structurilor de stabilizare a celulelor, cunoscute sub numele de microtubuli. Acest lucru este important deoarece se crede c\u0103 tau anormal se acumuleaz\u0103 \u00een celulele creierului, fiind legat de progresia afec\u021biunilor de demen\u021b\u0103, cum ar fi Alzheimer, demen\u021ba frontotemporal\u0103 (FTD) \u0219i paralizia supranuclear\u0103 progresiv\u0103. Speran\u021ba acestei cercet\u0103ri a fost de a dezvolta un instrument care s\u0103 poat\u0103 diagnostica cazurile de demen\u021b\u0103, precum \u0219i s\u0103 elimine \u00een siguran\u021b\u0103 tau toxic.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103?<\/h3>\n\n\n\n<p>Ca multe alte descoperiri din medicina modern\u0103, acest nou instrument provine din modificarea unui instrument mai vechi numit T807, care era o sond\u0103 molecular\u0103 utilizat\u0103 \u00een terapia cu emisie de pozitroni (PET). Dispozitivul original a fost folosit pentru a scana boala Alzheimer \u0219i alte boli legate de tau prin marcarea sondei cu un izotop radioactiv. C\u00e2nd acesta se leag\u0103 de tau anormal, o scanare PET poate detecta boala. Modificarea acestei sonde cu o molecul\u0103 ligand de recrutare a E3-ligazei permite sondei s\u0103 se lege de mecanismul celulei, distrug\u00e2nd celulele nedorite. Apoi, aceast\u0103 sond\u0103 recent revizuit\u0103 permite proteinei tau anormale s\u0103 se lege de proteina ubiquitin\u0103, care practic eticheteaz\u0103 proteina anormal\u0103 drept gunoi celular. Sonda modificat\u0103 QC-01-175 ac\u021bioneaz\u0103 ca un instrument pentru livrarea de tau toxic \u00een sistemul de eliminare a celulelor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Rezultatele<\/h3>\n\n\n\n<p>Rezultatul tuturor acestor lucr\u0103ri a fost o sond\u0103 care a reu\u0219it ceea ce cercet\u0103torii \u0219i-au propus s\u0103 realizeze. Proteina tau anormal\u0103 a fost eliminat\u0103, av\u00e2nd \u00een acela\u0219i timp efecte minime asupra proteinei tau \u00een neuronii voluntarilor s\u0103n\u0103to\u0219i. Aceasta este prima tehnic\u0103 de succes care vizeaz\u0103 proteina tau deteriorat\u0103 din neuronii umani. \u00cen al doilea r\u00e2nd, aceasta reprezint\u0103 modul \u00een care degradarea \u021bintit\u0103 a proteinelor poate transforma un liant proteic \u00eentr-o molecul\u0103 cu efecte farmacologice asupra celulelor. Aceast\u0103 strategie este explorat\u0103 \u00een tratarea unei game mai extinse de proteine care determin\u0103 neurodegenerarea; aceasta se afl\u0103 \u00eenc\u0103 \u00een stadiul de testare pe animale.<\/p>\n\n\n\n<p>Dac\u0103 a\u021bi fost diagnosticat cu orice form\u0103 de demen\u021b\u0103 \u0219i dori\u021bi o a doua opinie medical\u0103&nbsp;<a href=\"https:\/\/www.worldcare.com\/ro\/contact\/\">Contacta\u021bi-ne ast\u0103zi<\/a>.<\/p>\n\n\n\n<p>Surs\u0103:&nbsp;<a href=\"https:\/\/www.massgeneral.org\/about\/pressrelease.aspx?id=2386\" target=\"_blank\" rel=\"noopener\">https:\/\/www.massgeneral.org\/about\/pressrelease.aspx?id=2386<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>From successfully achieving the first remission of a pediatric cancer case in 1948, to creating the most revolutionary medical achievements\u00a0WorldCare Consortium\u00ae\u00a0medical second opinion (MSO) providers, Dana-Farber and Massachusetts General Hospital have successfully created a molecular tool that helps study the accumulation of toxic proteins in patient\u2019s brain cells who suffer from multiple dementia conditions. This [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3010,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[76,58,57,125,74],"class_list":["post-2968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dementia","tag-brain-health","tag-dementia","tag-diagnosis","tag-medical-innovation","tag-neurodegenerative-diseases"],"_links":{"self":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/posts\/2968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/comments?post=2968"}],"version-history":[{"count":0,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/posts\/2968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/media\/3010"}],"wp:attachment":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/media?parent=2968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/categories?post=2968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/tags?post=2968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}